Results 171 to 180 of about 81,723 (303)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Local prevalence and management of Janus kinase inhibitor-induced acne among adolescents with inflammatory bowel disease. [PDF]

Crohns Colitis 360
Barclay AIS, Hall CHT, Torres-Zegarra C, Guelfand Warnken S, White S, Constant B.   +5 more
europepmc   +1 more source

JI‐CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7‐H3

Cancer Science, EarlyView.
Schematic pathway diagram illustrating the effects of JI‐CJ002 and dabrafenib on melanoma progression. The combination of JI‐CJ002 and dabrafenib is associated with reduced B7‐H3 expression and modulation of signaling pathways implicated in melanoma progression, including JAK2/STAT3, PI3K/AKT/mTOR, and Rb/E2F1.
Sang‐Eun Lee, Young Ha Kim, Bo Shin Heo, Chunhoo Cheon, Seong‐Gyu Ko   +4 more
wiley   +1 more source

Flagellate erythema-like persistent eruption of Still's disease treated with a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Kassels A, Pham CT, Moon D, Lee BA, Rojek NW.   +4 more
europepmc   +1 more source

A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis. [PDF]

J Biol Chem, 2023
Bu Y, Traore MDM, Zhang L, Wang L, Liu Z, Hu H, Wang M, Li C, Sun D.   +8 more
europepmc   +1 more source

Multifunctional Role of Mitochondrial Fatty Acid Oxidation in Cancer Immunotherapy and Aging

Cancer Science, EarlyView.
Recent studies have highlighted the complex interplay between tumor immunity, aging, and inflammation. Mitochondrial FAO is a major hub of this physiological interplay. ABSTRACT Recent studies have demonstrated the intricate relationship between tumor immunity, aging, and inflammation.
Koji Kitaoka, Shuhei Hirose, Yu Wang, Tomonori Yaguchi, Kenji Chamoto   +4 more
wiley   +1 more source

Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis. [PDF]

Ann Med
Shuaib L, D Rai K, K Sangtiani A, Ishtiaq J, Mubeen M, Saeed A, Poudel S.   +6 more
europepmc   +1 more source

Latest Research Hot Spots of Atopic Dermatitis Management Using Janus Kinase Inhibitor: A Bibliometric Analysis and Visualized Review. [PDF]

Clin Cosmet Investig Dermatol
Nukaly H, AlHuraish DS, Bakhamees BH, AlHemli HA, Alsaadoon MS, Alhejji RK, Alotaibi G, Alomran SA, AlHalees Z.   +8 more
europepmc   +1 more source